Your browser doesn't support javascript.
loading
HBV confers innate immune evasion through triggering HAT1/acetylation of H4K5/H4K12/miR-181a-5p or KPNA2/cGAS-STING/IFN-I signaling.
Zhao, Lina; Yuan, Hongfeng; Wang, Yufei; Geng, Yu; Yun, Haolin; Zheng, Wei; Yuan, Ying; Lv, Pan; Hou, Chunyu; Zhang, Huihui; Sun, Jiao; Sun, Linlin; Suo, Yuhong; Wang, Shuai; Zhang, Ningning; Lu, Wei; Yang, Guang; Zhang, Xiaodong.
Afiliação
  • Zhao L; Department of Gastrointestinal Cancer Biology, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Cancer Institute, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Cl
  • Yuan H; Department of Gastrointestinal Cancer Biology, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Cancer Institute, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Cl
  • Wang Y; Department of Gastrointestinal Cancer Biology, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Cancer Institute, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Cl
  • Geng Y; Department of Cancer Research, Institute of Molecular Biology, College of Life Sciences, Nankai University, Tianjin, China.
  • Yun H; Department of Cancer Research, Institute of Molecular Biology, College of Life Sciences, Nankai University, Tianjin, China.
  • Zheng W; Department of Cancer Research, Institute of Molecular Biology, College of Life Sciences, Nankai University, Tianjin, China.
  • Yuan Y; Department of Cancer Research, Institute of Molecular Biology, College of Life Sciences, Nankai University, Tianjin, China.
  • Lv P; Department of Gastrointestinal Cancer Biology, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Cancer Institute, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Cl
  • Hou C; Department of Gastrointestinal Cancer Biology, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Cancer Institute, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Cl
  • Zhang H; Department of Gastrointestinal Cancer Biology, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Cancer Institute, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Cl
  • Sun J; Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China.
  • Sun L; Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China.
  • Suo Y; Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China.
  • Wang S; Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China.
  • Zhang N; Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China.
  • Lu W; Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China.
  • Yang G; Department of Gastrointestinal Cancer Biology, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Cancer Institute, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Cl
  • Zhang X; Department of Gastrointestinal Cancer Biology, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Cancer Institute, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Cl
J Med Virol ; 95(7): e28966, 2023 07.
Article em En | MEDLINE | ID: mdl-37466313
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: MicroRNAs / Hepatite B Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Med Virol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: MicroRNAs / Hepatite B Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Med Virol Ano de publicação: 2023 Tipo de documento: Article